Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 72 peer-reviewed journal articles Updated
Oncology · Extranodal Nasal NK/T-Cell Lymphoma

Understanding Extranodal Nasal NK/T-Cell Lymphoma

At a Glance

Extranodal nasal NK/T-cell lymphoma (ENKTL) is a rare, aggressive cancer of the immune system that usually begins in the nasal area. It is strongly linked to the Epstein-Barr virus (EBV), and standard treatment typically involves a combination of specialized chemotherapy and radiation therapy.

A diagnosis of Extranodal nasal NK/T-cell lymphoma (ENKTL) can feel overwhelming, especially because it is rare and classified as an aggressive lymphoma (a fast-growing cancer of the immune system) [1][2]. While the name is complex, understanding the basic nature of this disease is the first step toward regaining control. ENKTL is a distinct type of non-Hodgkin lymphoma that primarily involves the nasal area but can also appear in other parts of the body [3][4].

Where It Occurs and Who It Affects

ENKTL is highly geographic, meaning it is much more common in certain parts of the world than others. While it makes up less than 1% of lymphomas in Western countries, it is significantly more frequent in East Asia and Central and South America [5][6]. In some regions of China, for example, it can account for over 50% of certain T-cell lymphomas [7]. In the United States, although it remains rare, incidence has nearly doubled over the last decade, particularly among Hispanic populations [8].

The Role of the Epstein-Barr Virus (EBV)

One of the most defining features of ENKTL is its near-universal link to the Epstein-Barr virus (EBV) [9][1]. EBV is a very common virus—the same one that causes infectious mononucleosis (“mono”)—and most people carry it without ever getting cancer. However, in ENKTL, the virus enters NK cells (Natural Killer cells) or T cells (types of white blood cells) and causes them to multiply uncontrollably [10][11].

Because of this link, doctors use EBV-DNA levels in the blood as a critical tool [12]. This “viral load” helps your care team:

  • Confirm the diagnosis: High levels of EBV-DNA are a hallmark of the disease [13].
  • Track treatment progress: Monitoring these levels helps show how well the cancer is responding to therapy [14].
  • Predict outcomes: The amount of EBV-DNA in your blood before treatment starts is a key factor in determining your individual risk profile [15].

Understanding the Diagnosis

Doctors use several specialized tests to confirm ENKTL and differentiate it from other conditions. The “gold standard” for diagnosis is a test called EBER-ISH, which looks for the virus directly inside the tumor cells [11].

Other important tools include:

  • Imaging: An FDG-PET/CT scan is pivotal for seeing exactly where the lymphoma is located and how active it is [16][17].
  • Biopsy: A tissue sample is examined for an angiocentric growth pattern, where the lymphoma cells surround and invade blood vessels [18].
  • Staging: Your doctor will look at your Ann Arbor stage (the spread of the disease), the presence of B symptoms (fever, night sweats, or weight loss), and your general health (performance status) to create a tailored treatment plan [19][20].

Moving Forward with Confidence

Although ENKTL is aggressive, modern medical guidelines have established clear, effective protocols for treating it. Current international consensus and NCCN (National Comprehensive Cancer Network) guidelines emphasize using specialized treatment plans that often combine chemotherapy and radiotherapy (radiation) [21][1]. Because ENKTL is unique and differs from more common lymphomas, having a treatment plan specifically designed for this “nasal-type” lymphoma is essential for the best possible results [21][22].

Navigating This Guide

To help you understand your diagnosis and prepare for your next steps, we have broken down the information into specific sections:

01

Recognizing Symptoms and Warning Signs

Learn to recognize the early symptoms of Extranodal Nasal NK/T-Cell Lymphoma (ENKTL). Discover why it mimics sinus infections and when to ask for a biopsy.

02

Your Biology and Pathology Report

Learn how to read your Extranodal Nasal NK/T-cell Lymphoma (ENKTL) pathology report. Understand EBV testing, CD56, EBER-ISH, and what your results mean.

03

Staging and Understanding Your PINK-E Risk Score

Learn how Extranodal nasal NK/T-cell lymphoma (ENKTL) is staged using the Ann Arbor system and the specialized PINK-E risk score to guide your treatment.

04

Current Standard of Care and Treatment Options

Learn the standard of care for Extranodal Nasal NK/T-cell Lymphoma (ENKTL). Understand why regimens like DDGP, L-asparaginase, and CCRT are used over CHOP.

05

Survivorship and Life After Treatment

Learn what to expect after ENKTL treatment. Discover your follow-up scan schedule, how EBV-DNA monitoring works, and ways to manage long-term side effects.

Finding Support

Because ENKTL is a rare subtype of lymphoma, connecting with specialized support networks can be invaluable. Organizations like the T-Cell Leukemia Lymphoma Foundation (TCLLF) and the Cutaneous Lymphoma Foundation can help you find communities of patients who understand the unique challenges of rare T-cell and NK-cell lymphomas.

Common questions in this guide

What is Extranodal Nasal NK/T-Cell Lymphoma (ENKTL)?
ENKTL is a rare, fast-growing type of non-Hodgkin lymphoma that typically starts in the nasal passages. It is closely linked to the Epstein-Barr virus and requires a specialized treatment plan.
Why does my doctor check my Epstein-Barr virus (EBV) levels?
Checking EBV-DNA levels in your blood helps your doctors confirm an ENKTL diagnosis and track your progress. High levels are a hallmark of this disease, and monitoring them shows how well your cancer is responding to treatment.
What is the EBER-ISH test used for?
The EBER-ISH test is the gold standard for diagnosing ENKTL. It looks directly inside the tumor cells to detect the presence of the Epstein-Barr virus, which confirms the exact type of lymphoma you have.
What are B symptoms in lymphoma?
B symptoms refer to specific systemic warning signs, including fevers, severe night sweats, and unexplained weight loss. Your care team tracks these symptoms closely to help determine the stage of your lymphoma and tailor your treatment plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current plasma EBV-DNA level, and how will we monitor this during my treatment?
  2. 2.Has my diagnosis been confirmed using EBER-ISH testing?
  3. 3.What stage is my lymphoma based on the PET/CT scan, and what is my risk score?
  4. 4.Are we using a treatment plan that combines both chemotherapy and radiation?
  5. 5.Is the care team here experienced in treating this specific, rare type of lymphoma?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment.

    van Doesum JA, Niezink AGH, Huls GA, et al.

    HemaSphere 2021; (5(2)):e523 doi:10.1097/HS9.0000000000000523.

    PMID: 33458595
  2. 2

    Primary small intestinal extranodal NK/T cell lymphoma, nasal type with kidney involvement: a rare case report and literature review.

    Mao S, Diao C, Cao L

    Diagnostic pathology 2022; (17(1)):75 doi:10.1186/s13000-022-01254-z.

    PMID: 36199094
  3. 3

    Diagnostic approach to T- and NK-cell lymphoproliferative disorders in the gastrointestinal tract.

    Susan SH, Ng SB, Wang S, Tan SY

    Seminars in diagnostic pathology 2021; (38(4)):21-30 doi:10.1053/j.semdp.2021.03.004.

    PMID: 34016481
  4. 4

    JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK/T-cell lymphoma, nasal type (ENKL).

    Yamaguchi M, Suzuki R

    International journal of hematology 2019; (109(4)):371-376 doi:10.1007/s12185-019-02609-x.

    PMID: 30820835
  5. 5

    Primary Breast Natural Killer/T-cell lymphoma with Cutaneous Involvement: A Case Report.

    Wu H, Jin SY

    Alternative therapies in health and medicine 2023; (29(8)):252-254.

    PMID: 37573597
  6. 6

    Case of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Presenting With Intravascular Localization of Tumor Cells in Skin Biopsies From Both Plaque and Normal-Appearing Skin: A Case Report and Literature Review.

    Obara K, Amoh Y

    The American Journal of dermatopathology 2020; (42(3)):196-203 doi:10.1097/DAD.0000000000001523.

    PMID: 31567394
  7. 7

    Pathological profile of 1,385 lymphoma cases in Zunyi, China: A classification-based analysis following the WHO 2022 criteria for hematolymphoid tumors.

    Ji Q, Su J, Zhang S, et al.

    Virchows Archiv : an international journal of pathology 2025; (487(5)):1127-1135 doi:10.1007/s00428-025-04299-9.

    PMID: 41102488
  8. 8

    Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States.

    Kommalapati A, Tella SH, Ganti AK, Armitage JO

    Clinical lymphoma, myeloma & leukemia 2018; (18(7)):475-479 doi:10.1016/j.clml.2018.04.009.

    PMID: 29752210
  9. 9

    Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

    Haverkos BM, Coleman C, Gru AA, et al.

    Discovery medicine 2017; (23(126)):189-199.

    PMID: 28472613
  10. 10

    Extranodal NK/T cell lymphoma and aggressive NK cell leukaemia: evidence for their origin on CD56+bright CD16-/+dim NK cells.

    Lima M

    Pathology 2015; (47(6)):503-14 doi:10.1097/PAT.0000000000000275.

    PMID: 26166665
  11. 11

    Peripheral T cell lymphoma of the nasopharynx with expansion of EBV-positive B cells masquerading as an extranodal NK/T cell lymphoma, nasal type.

    Kim HN, Kim DS, Jeon MJ, et al.

    Virchows Archiv : an international journal of pathology 2022; (481(1)):125-129 doi:10.1007/s00428-021-03240-0.

    PMID: 34997312
  12. 12

    Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.

    Tse E, Au-Yeung R, Kwong YL

    Expert review of hematology 2019; (12(11)):927-935 doi:10.1080/17474086.2019.1660640.

    PMID: 31487202
  13. 13

    The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis.

    Liu ZL, Bi XW, Liu PP, et al.

    Disease markers 2018; (2018()):1961058 doi:10.1155/2018/1961058.

    PMID: 30581497
  14. 14

    Extranodal natural killer/T-cell lymphoma coexisting with peripheral T-cell lymphoma, not otherwise specified.

    Hayashino K, Yoshida C, Ayata Y, et al.

    Journal of clinical and experimental hematopathology : JCEH 2024; (64(1)):52-58 doi:10.3960/jslrt.23049.

    PMID: 38538319
  15. 15

    Prognostic significance of Epstein-Barr virus DNA in NK/T-cell lymphoma: a meta-analysis.

    Fei Q, Tian XK, Wu J, et al.

    OncoTargets and therapy 2018; (11()):997-1004 doi:10.2147/OTT.S153942.

    PMID: 29520150
  16. 16

    The role of 18F-FDG PET/CT in diagnosing cardiac infiltration and therapeutic evaluation in extranodal nasal-type NK/T-cell lymphoma: a case report.

    Liao T, Li L, Fu G, et al.

    Frontiers in oncology 2025; (15()):1548785 doi:10.3389/fonc.2025.1548785.

    PMID: 40123904
  17. 17

    Appropriate timing to perform an interim 18F-FDG PET/CT in patients with nasal-type extranodal natural killer/T cell lymphoma.

    Wang R, Zhang Y, Fan Q, et al.

    Annals of hematology 2024; (103(3)):885-892 doi:10.1007/s00277-023-05562-2.

    PMID: 38030892
  18. 18

    A case of primary pulmonary NK/T cell lymphoma presenting as pneumonia.

    Lee S, Shin B, Yoon H, et al.

    Respiratory medicine case reports 2016; (17()):1-4 doi:10.1016/j.rmcr.2015.11.003.

    PMID: 27141431
  19. 19

    [Extranodal NK/T-cell lymphoma, nasal type: a clinical analysis].

    Chen F, Shen CX, Wang HG, et al.

    Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery 2017; (31(5)):327-333 doi:10.13201/j.issn.1001-1781.2017.05.001.

    PMID: 29871255
  20. 20

    [Survival and Prognosis of Patients with Nasal NK/T-Cell Lymphoma].

    Xie DN, Li YH, Chen XJ, et al.

    Zhongguo shi yan xue ye xue za zhi 2020; (28(2)):507-511 doi:10.19746/j.cnki.issn.1009-2137.2020.02.025.

    PMID: 32319387
  21. 21

    Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.

    Chaubard S, Marouf A, Lavergne D, et al.

    British journal of haematology 2023; (201(4)):673-681 doi:10.1111/bjh.18689.

    PMID: 36799516
  22. 22

    Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).

    Yoon DH, Kim SJ, Jeong SH, et al.

    Oncotarget 2016; (7(51)):85584-85591 doi:10.18632/oncotarget.11319.

    PMID: 27542213

This page provides educational information about Extranodal Nasal NK/T-Cell Lymphoma (ENKTL). It is not a substitute for professional medical advice, diagnosis, or treatment from your oncology team.

Get notified when new evidence is published on Extranodal nasal NK/T cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.